Applied Therapeutics, Inc. (APLT) News
Filter APLT News Items
APLT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
APLT News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest APLT News From Around the Web
Below are the latest news stories about APPLIED THERAPEUTICS INC that investors may wish to consider to help them evaluate APLT as an investment opportunity.
Is Applied Therapeutics (APLT) the Best Penny Stock to Invest In According to Media?We recently compiled a list of the 12 Best Penny Stocks to Invest in According to the Media. In this article, we are going to take a look at where Applied Therapeutics, Inc. (NASDAQ:APLT) stands against other penny stocks to buy according to the media. Small-Cap Stocks Outlook for 2025 On December 24, Global Advisors’ […] |
Here’s Why Applied Therapeutics, Inc. (NASDAQ:APLT) Is Among the Best Diabetes Stocks to Buy Under $10We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at where Applied Therapeutics, Inc. (NASDAQ:APLT) stands against the other diabetes stocks. Global Growth and Innovation in Diabetes Care: The Rise of Continuous Glucose Monitors and AI Integration About 422 million […] |
Penny Stock Applied Therapeutics' FDA Troubles Trigger Investor Lawsuit, Shareholders Claim Deception Over Govorestat Clinical DataAdrian Alexandru, representing all similarly affected investors, has filed a federal securities class-action lawsuit against Applied Therapeutics (NASDAQ:APLT), alleging the company violated federal securities laws. The lawsuit claims that the company provided misleading information about its clinical trials and failed to disclose key adverse facts, causing significant financial losses for shareholders. Also Read: Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbust |
Applied Therapeutics Appoints John H. Johnson as Executive ChairmanShoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr |
Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Applied Therapeutics Faces Uncertainty After US FDA Rejects NDA for Govorestat in Galactosemia, UBS SaysApplied Therapeutics (APLT) faces uncertainty after the US Food and Drug Administration rejected the |
Company News for Dec 2, 2024Companies in The News Are: APLT,TGT,WMT,AAPL |
Applied Therapeutics CRL a ‘major setback,’ says William BlairWilliam Blair says Applied Therapeutics (APLT)’ complete response letter from the FDA for govorestat for the treatment of galactosemia is “unexpected and disappointing.” Given the lack of information in the CRL, it is unclear what the path forward for govorestat in galactosemia is and whether an additional clinical trial will be necessary for approval in this indication, the analyst tells investors in a research note. The firm says that while the rejection is a “major setback,” there is a possib |
Applied Therapeutics downgraded to Sector Perform from Outperform at RBCRBC Capital analyst Brian Abrahams downgraded Applied Therapeutics (APLT) to Sector Perform from Outperform with a price target of $4, down from $12. The complete response letter for govorestat in galactosemia is disappointing and “creates significant uncertainties” around a future path forward for the drug in that indication, the analyst tells investors in a research note. The firm still sees “meaningful residual value” from sorbitol dehydrogenase deficiency where a new drug application submiss |
FDA Rejects Applied Therapeutics' NDA for Govorestat, Citing Flaws; Shares Plunge 76%The company plans to request a meeting with the FDA to discuss potential resubmission |